Risk factors for reactivation of clinical disease activity in multiple sclerosis after natalizumab cessation

ConclusionHigh disease activity and a high level of disability prior to NTZ treatment seem to predict disease reactivation after treatment cessation. When switching to subsequent DMDs, the washout time should not exceed 3 months. However, subsequent DMDs failed to prevent the reactivation of MS in this cohort.
Source: Multiple Sclerosis and Related Disorders - Category: Neurology Source Type: research